zanamivir

Zanamivir (GG167) is a guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.

Di(zanamivir-amide(N-Me)-PEG1)-N-PEG4-alkyne is a conjugate of Zanamivir (a neuraminidase inhibitor for viruses) and a linker. It is used in the study of viral infections.

Zanamivir hydrate is neuraminidase inhibitors. It is used worldwide for the treatment and prophylaxis of influenza caused by influenza A and B viruses.

Zanamivir-13C,15N2 is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir (T2529) is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.

Zanamivir-CoA (Zanamivir-coenzyme A) is a derivative of coenzyme A.

Zanamivir amine, a neuraminidase inhibitor, exhibits antiviral activity by effectively curbing the proliferation of influenza viruses. Clinically, it is utilized to suppress influenza infections by interfering with the viral replication process, thereby reducing viral load.